India’s market and global opportunities

Date: 28th Oct 2024 | Publication: Ausbiz Mugunthan Siva of India Avenue Investment Management shares insights on India’s thriving pharmaceutical industry. With 25% of the world’s FDA-approved facilities, India supplies nearly 40% of America’s generic medications. This competitive edge presents global opportunities. Mugunthan highlights India’s pharma sector, which composes 5% of MSCI India, compared to his fund’s 20% exposure. He states India’s pharmaceutical growth is set to outpace the global markets, particularly with upcoming patent cliffs benefiting Indian exports. Mugunthan notes increasing trade between India and China, emphasising the importance of balanced partnerships. He mentions India’s IT sector, which is growing and adding workforce capacity. An ETF based on this fund is set for launch by year’s end.